Advanced search
Publication Cover
OncoImmunology Volume 3, 2014 - Issue 6
Submit an article Journal homepage
636
Views
4
CrossRef citations to date
0
Altmetric
Author's View

BRAF-targeted therapy alters the functions of intratumoral CD4+ T cells to inhibit melanoma progression

Ping-Chih Ho Department of Immunobiology; Yale University School of Medicine; New Haven, CT USA
&
Susan M Kaech Department of Immunobiology; Yale University School of Medicine; New Haven, CT USA; Howard Hughes Medical Institute; Chevy Chase, MD USACorrespondence[email protected]
Article: e29126 | Received 30 Apr 2014, Accepted 06 May 2014, Published online: 18 Jun 2014

References

  • Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694 - 703; http://dx.doi.org/10.1056/NEJMoa1210093; PMID: 23020132
  • Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, Hirth P. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012; 11:873 - 86; http://dx.doi.org/10.1038/nrd3847; PMID: 23060265
  • Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960 - 4; http://dx.doi.org/10.1126/science.1129139; PMID: 17008531
  • Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011; 25:2559 - 72; http://dx.doi.org/10.1101/gad.169029.111; PMID: 22190457
  • Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237 - 51; http://dx.doi.org/10.1038/nrc3237; PMID: 22437869
  • Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013; 123:1371 - 81; http://dx.doi.org/10.1172/JCI66236; PMID: 23454771
  • Ho PC, Meeth KM, Tsui YC, Srivastava B, Bosenberg MW, Kaech SM. Immune-based antitumor effects of BRAF Inhibitors rely on signaling by CD40L and IFNγ. Cancer Res 2014; ; In press http://dx.doi.org/10.1158/0008-5472.CAN-13-3461; PMID: 24736544
  • Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr., You MJ, DePinho RA, McMahon M, Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41:544 - 52; http://dx.doi.org/10.1038/ng.356; PMID: 19282848
  • De Palma M, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23:277 - 86; http://dx.doi.org/10.1016/j.ccr.2013.02.013; PMID: 23518347

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.